Tanı Anında Bakılan Serum 25 Hidroksi Vitamin D Düzeyinin Meme Kanseri Prognozu Üzerine Etkisi

Abstract

Breast cancer is the most frequently diagnosed cancer in women. In studies it has been shown that vitamin D may play a role in breast cancer prognosis. Vitamin D has been emphasized to inhibit development and progression of breast cancer by inhibiting tumor cell proliferation and angiogenesis but it has not been documented exactly. The purpose of this study is to investigate the effect of serum vitamin D level at the time of diagnosis on breast cancer. Two hundred women diagnosed with breast cancer between 2010-2013 years were included in the study (according to TNM classification, 54 patients in stage 1, 55 patients in stage 2, 55 patients in stage 3, 36 patients in stage 4). Serum 25 hydroxyvitamin D (25[OH]D) levels were measured in the serum of patients which had been taken at the time of diagnosis of breast cancer and kept at -80 ºC. The relationship between serum vitamin D level and breast cancer prognostic factors was investigated. Median follow-up time of patients was 38.7 months. Average age of patients was 49.8 ± 11.9 years. There was no statistically significance between serum vitamin D sufficiency status, median vitamin D levels and patients’ demographic characteristics, comorbidities, tumor histologic types, hormone receptor and HER2/neu status, medical and surgical therapy types, response to treatment, survival status. There was a statistically significant relationship between breast cancer stage and vitamin D sufficiency status (p=0.033). Serum vitamin D levels were sufficient in 12 patients (22.2%) at stage 1, in 1 patient (1.8%) at stage 2, in 6 patients (10.9%) at stage 3 and in 6 patients (16.7%) at stage 4 breast cancer. Median serum vitamin D level was lower in patients with lymph node involvement than without (7.6 μg/L vs. 12.4 μg/L p=0.038). In this study, a relationship has been shown between lymph node involvement and serum vitamin D level. No relationship between serum vitamin D level and breast cancer survival may depend on the short duration of follow-up period.